Min Li, Ma Ruo-Lan, Yuan Hua, Liu Cai-Yun, Dong Bing, Zhang Cheng, Zeng Yan, Wang Li, Guo Jian-Ping, Qu Li-Ke, Shou Cheng-Chao
Department of Biochemistry and Molecular Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China E-mail :
Asian Pac J Cancer Prev. 2015;16(7):2819-26. doi: 10.7314/apjcp.2015.16.7.2819.
Combinations of multiple biomarkers representing distinct aspects of metastasis may have better prognostic value for breast cancer patients, especially those in late stages. In this study, we evaluated the protein levels of N-α-acetyltransferase 10 protein (Naa10p), synuclein-γ (SNCG), and phosphatase of regenerating liver-3 (PRL-3) in 365 patients with breast cancer by immunohistochemistry. Distinct prognostic subgroups of breast cancer were identified by combination of the three biomarkers. The Naa10p+SNCG-PRL-3- subgroup showed best prognosis with a median distant metastasis-free survival (DMFS) of 140 months, while the Naa10p-SNCG+PRL-3+ subgroup had the worst prognosis with a median DMFS of 60.5 months. Multivariate analysis indicated Naa10p, SNCG, PRL-3, and the TNM classification were all independent prognostic factors for both DMFS and overall survival (OS). The three biomarker combination of Naa10p, SNCG and PRL-3 performed better in patients with lymph node metastasis, especially those with more advanced tumors than other subgroups. In conclusion, the combined expression profile of Naa10p, SNCG and PRL-3, alone or in combination with the TNM classification system, may provide a precise estimate of prognosis of breast cancer patients.
代表转移不同方面的多种生物标志物组合可能对乳腺癌患者具有更好的预后价值,尤其是晚期患者。在本研究中,我们通过免疫组织化学评估了365例乳腺癌患者中N-α-乙酰基转移酶10蛋白(Naa10p)、突触核蛋白-γ(SNCG)和再生肝磷酸酶-3(PRL-3)的蛋白水平。通过这三种生物标志物的组合确定了不同的乳腺癌预后亚组。Naa10p+SNCG-PRL-3-亚组预后最佳,中位无远处转移生存期(DMFS)为140个月,而Naa10p-SNCG+PRL-3+亚组预后最差,中位DMFS为60.5个月。多变量分析表明,Naa10p、SNCG、PRL-3和TNM分类都是DMFS和总生存期(OS)的独立预后因素。Naa10p、SNCG和PRL-3这三种生物标志物组合在有淋巴结转移的患者中表现更好,尤其是那些肿瘤比其他亚组更晚期的患者。总之,Naa10p、SNCG和PRL-3的联合表达谱,单独或与TNM分类系统联合,可能为乳腺癌患者的预后提供精确评估。